This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Y-mAbs Therapeutics’s 8K filing here.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Featured Articles
- Five stocks we like better than Y-mAbs Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Delta Can Fly to New Highs in 2025; Here’s Why
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Snowflake Stock: Bullish Upgrades Demand Investors’ Attention
- What Are Dividend Challengers?
- 3 Dividend Stocks With Growth Potential You Can’t Miss
